<DOC>
	<DOC>NCT02709746</DOC>
	<brief_summary>Evaluating the efficacy of vortioxetine 10 mg/day and 20 mg/day versus placebo on depressive symptoms in adolescents (age ≥12 and ≤17 years) with a DSM-5™ (Diagnostic and Statistical Manual of Mental Disorders, 5th edition) diagnosis of Major depressive disorder (MDD).</brief_summary>
	<brief_title>Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>The patient is a male or female, aged ≥12 and ≤17 years at Screening (patients who turn 18 years during the study will be allowed to continue in the study). The patient has Major depressive disorder (MDD), diagnosed according to DSM5™. The patient has a CDRSR total score ≥45 at the Screening Visit and at the Baseline. The patient has a CGIS score ≥4 at the Screening Visit and at the Baseline The patient has provided assent to participation and parent(s)/legal representative (s) signed the Informed Consent Form. The patient has participated in a clinical study &lt;30 days prior to the Screening Visit. Other protocol defined inclusion and exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>paediatric patients</keyword>
</DOC>